Urelumab

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameUrelumab
Drug Alias Name乌瑞芦单抗Urelumabum乌瑞鲁单抗BMS-66513BMS-663513
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor receptor superfamily member 9 agonists
TargetsTumor necrosis factor receptor superfamily member 9
Therapy Area/IndicationsSkin MelanomaSolid tumoursUrinary Bladder Neoplasms +[18] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesItaly +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb Srlcompany
Inactive CompaniesThe University Of Texas MD Anderson Cancer CenterUniversity Of NavarraClinica Universidad De Navarra +[4] 
Active IndicationsUrinary Bladder NeoplasmsBrain NeoplasmsCarcinoma, Transitional Cell +[5] 
Inactive IndicationsSkin MelanomaSolid tumoursCarcinoma, Non-Small-Cell Lung +[13] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG